Search This Blog

Friday, February 28, 2025

ImmunityBio stock climbs on FDA RMAT designation

 ImmunityBio (NASDAQ:IBRX) stock rose 10% Friday morning after the company said it has received Regenerative Medicine Advanced Therapy designation for Anktiva and CAR-NK, or PD-L1 t-haNK.

The designation is for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in the treatment of multiply relapsed locally advanced or metastatic pancreatic cancer, according to a statement. 

ImmunityBio (NASDAQ:IBRX) added that it plans to file an Expanded Access Policy for Anktiva and PD-L1 t-haNK in combination with standard of care chemotherapy/radiotherapy within fifteen days and submit the protocol to the FDA.

https://www.msn.com/en-us/health/other/immunitybio-stock-climbs-10-on-fda-rmat-designation/ar-AA1zZE9t

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.